are any of your mets amenable to biopsy? A recent lecture I attended by Stefanie Jeffrey of Stanford reported the results of a study (to be published in June) of Circulating tumor cells in patients with metastatic breast cancer and their genetic make-up. CTCs were found to be very heterogeneous and in two cases studied of patients with metastatic her2+ bc patients ON HERCEPTIN, there were triple negative CTCS among their CTCs. Their preliminary recommendation was to perhaps treat these patients with dasatinib in order to keep those CTCs or the sites of micrometastasis from which they came/went from fluorishing as triple negative metastases.
If your disease now has a different genetic makeup than your primary disease did, perhaps different targetted and chemotherapies might be used.
I have been reviewing hundreds of abstracts from the upcoming asco meeting and these include mentions of various ongoing trials AND THERE ARE MANY .
To find the abstracts, go to
www.asco.org and click on the area for online abstracts just posted.
I hope some of this is helpful! I am sure all of our best wishes and prayers are with you.